Table 1.
Baseline details of patients in both arms
| Variable | Arm A (gefitinib arm) | Arm B (pemetrexed–platinum arm) |
| Mean age | 54.44 years | 53.12 years |
| Elderly status (≥65 years) | ||
| Gender | ||
| Male | 67 (46.2%) | 97 (66.9%) |
| Female | 78 (53.8%) | 48 (33.1%) |
| Smoking status | ||
| Never smoker | 113 (77.9%) | 117 (80.7%) |
| Ex-smoker | 32 (22.1%) | 28 (19.3%) |
| Tobacco habit status | ||
| Present | 52 (35.9%) | 59 (40.7%) |
| Absent | 93 (64.1%) | 86 (59.3%) |
| ECOG PS | ||
| PS-0 | 3 (2.1%) | 2 (1.4%) |
| PS-1 | 132 (91.0%) | 136 (93.8%) |
| PS-2 | 10 (6.9%) | 7 (4.8%) |
| Stage | ||
| 3 | 2 (1.4%) | 3 (2.1%) |
| 4 | 143 (98.6%) | 142 (97.9%) |
| Presence of brain metastasis | 22 (15.7%) | 23 (15.9%) |
| Presence of liver metastasis | 35 (24.1%) | 40 (27.6%) |
| EGFR mutation status Exon 18 (G719C point mutation) | 4 (2.8%) | 2 (1.4%) |
| Exon 19 | 76 (52.4%) | 92 (63.4%) |
| Exon 21 | 65 (44.8%) | 51 (35.2%) |
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor.